SPA17

Across TCGA pan-cancer cohorts, SPA17 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SPA17 data layer compared with 28 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher SPA17 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SPA17 expression acts as an unfavorable survival marker, although some lineages such as LSCC and CCRCC show a favorable association.

LSCC, CCRCC, and LUAD are the cancer types where SPA17 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	III,IV	0.923	0.492	.017	5	view →
CCRCC	DFS	Median	All	1.000	0.544	.009	5	view →
LUAD	OS	Median	All	0.672	0.937	.026	1	view →
HNSC	DFS	Median	All	0.921	0.600	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SPA17–LSCC (OS)

Open the LSCC breakdown →